Home | Business News | Browse by Publication | P | Pharma Marketletter

Aventis' Taxotere improves survival in men with prostate cancer.

Publication: Pharma Marketletter
Publication Date: 14-JUN-04
Format: Online - approximately 473 words
Delivery: Immediate Online Access

Article Excerpt
Data presented at the annual meeting of the American Society of Clinical Oncology in New Orleans show that regimens containing Aventis' Taxotere (docetaxel) Injection Concentrate significantly improve survival in men with androgen-independent (hormone-refractory) metastatic prostate cancer. Based on these findings, the agent was recently approved for this indication, in combination with prednisone, by the US Food and Administration (Marketletter May 24).

The two landmark Phase III trials, TAX327 and SWOG...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Tarceva shows promise for NSCLC.(Brief Article), June 14, 2004
EU regulators alter Crestor label.(Brief Article), June 14, 2004
Vanda licences global rights to iloperidone from Novartis.(Brief Artic..., June 14, 2004
Medarex' MDX-010 granted Orphan Drug Status.(Brief Article), June 14, 2004

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.